Literature DB >> 2862415

Immunoreactive uroporphyrinogen decarboxylase in the liver in porphyria cutanea tarda.

G H Elder, A J Urquhart, R E De Salamanca, J J Munoz, H L Bonkovsky.   

Abstract

Immunoreactive and catalytic uroporphyrinogen decarboxylase were measured in liver from 15 patients with sporadic porphyria cutanea tarda (PCT) and 4 patients with familial PCT at different stages of the disorder. In sporadic PCT, catalytic activity was lowest and immunoreactive enzyme concentration was highest when active skin lesions were present; this pattern was also seen in the one familial PCT patient who had skin lesions. During remission, the ratio of catalytic activity to immunoreactive enzyme concentration returned towards normal. Immunoreactive enzyme was increased by comparison with controls in sporadic patients with skin lesions; in familial PCT mean concentration was 59% of the overall sporadic value. In 4 sporadic patients in prolonged (4-8 years) remission (following venesection) enzyme activity and immunoreactive enzyme concentrations were normal. It is suggested that clinically overt PCT is precipitated by an iron-dependent process which inactivates the active centres of uroporphyrinogen decarboxylase molecules in the liver. Treatment by venesection eventually leads to complete reversal of this biochemical defect in at least some patients with sporadic PCT. The findings are consistent with the view that sporadic PCT is an acquired disorder.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2862415     DOI: 10.1016/s0140-6736(85)90287-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  20 in total

1.  Porphyria cutanea tarda due to ferrous gluconate.

Authors:  A D Ginsburg; L J Margesson; K Feleki
Journal:  CMAJ       Date:  1990-10-15       Impact factor: 8.262

2.  Dramatic resolution of skin lesions associated with porphyria cutanea tarda after interferon-alpha therapy in a case of chronic hepatitis C.

Authors:  M Y Sheikh; R A Wright; J B Burruss
Journal:  Dig Dis Sci       Date:  1998-03       Impact factor: 3.199

Review 3.  Heme biosynthesis and the porphyrias.

Authors:  John D Phillips
Journal:  Mol Genet Metab       Date:  2019-04-22       Impact factor: 4.797

Review 4.  Murine models of the human porphyrias: Contributions toward understanding disease pathogenesis and the development of new therapies.

Authors:  Makiko Yasuda; Robert J Desnick
Journal:  Mol Genet Metab       Date:  2019-01-18       Impact factor: 4.797

Review 5.  Role of HFE gene mutations in liver diseases other than hereditary hemochromatosis.

Authors:  H L Bonkovsky; J V Obando
Journal:  Curr Gastroenterol Rep       Date:  1999 Feb-Mar

6.  Uroporphyria produced in mice by 20-methylcholanthrene and 5-aminolaevulinic acid.

Authors:  A J Urquhart; G H Elder; A G Roberts; R W Lambrecht; P R Sinclair; W J Bement; N Gorman; J A Sinclair
Journal:  Biochem J       Date:  1988-07-15       Impact factor: 3.857

7.  Genetic variation of iron-induced uroporphyria in mice.

Authors:  A G Smith; J E Francis
Journal:  Biochem J       Date:  1993-04-01       Impact factor: 3.857

Review 8.  HFE gene in primary and secondary hepatic iron overload.

Authors:  Giada Sebastiani; Ann-P Walker
Journal:  World J Gastroenterol       Date:  2007-09-21       Impact factor: 5.742

9.  Mechanistic studies of the inhibition of hepatic uroporphyrinogen decarboxylase in C57BL/10 mice by iron-hexachlorobenzene synergism.

Authors:  A G Smith; J E Francis; S J Kay; J B Greig; F P Stewart
Journal:  Biochem J       Date:  1986-09-15       Impact factor: 3.857

10.  An unhappy triad: hemochromatosis, porphyria cutanea tarda and hepatocellular carcinoma-a case report.

Authors:  Martina-T Mogl; Andreas Pascher; Sabine-J Presser; Michael Schwabe; Peter Neuhaus; Natascha-C Nuessler
Journal:  World J Gastroenterol       Date:  2007-04-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.